The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty.
JAM provides authors rapid publication of results via electronic published ahead-of-print and the Ovid platform, easily navigable manuscript submission software, and a steadily growing ISI Impact Factor. JAM is read by one of the largest addiction-specialty physician readerships on the globe: ASAM members as well as their professional colleagues. Additionally, JAM was accepted for citation in June 2011 by the National Library of Medicine. This development facilitates increased dissemination of content and has since been augmented with significantly expanded pagination. Since inception, JAM has been cited by peer-reviewed global search engines, including PubMed/NLM, BIOSIS Previews, PsychINFO, Ebsco A-Z, CNKI – The China National Knowledge Infrastructure, ProQuest Summons, Sage Knowledge, SWETS, TDNet, and Journal Guide.
Published six times a year, the Journal is designed for all physicians and other mental health professionals who need to keep up-to-date with the treatment of addiction disorders. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including:
•addiction and substance use in pregnancy
•adolescent addiction and at-risk use
•the drug-exposed neonate
•all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances
•treatment of special populations
•treatment, early intervention and prevention of alcohol and drug use disorders
•methodological issues in addiction research
•pain and addiction, prescription drug use disorder
•co-occurring addiction, medical and psychiatric disorders
•pathological gambling disorder, sexual and other behavioral addictions
•pathophysiology of addiction
•behavioral and pharmacological treatments
•issues in graduate medical education
•health services delivery
•ethical, legal and liability issues in addiction medicine practice
•self- and mutual-help
Publication & Editorial Staff Contacts
(678) 560-2810 | [email protected]
For Translation approval, License to republish and distribute,
Permission to reuse material in another publication or presentation,
please email one of the following:
LWW Business Offices
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103
Richard Saitz, MD, MPH, DFASAM, FACP
Kelly E. Dunn, PhD
Ismene Petrakis, MD
Martha J. Wunsch, MD, FAAP, DFASAM
Frank J. Vocci, PhD
Debbie M. Cheng, Sc.D.
Boston University School of Public Health
Charles Maynard, PhD
University of Washington
Michael A. Arends
Richard Saitz, MD, MPH, DFASAM, FACP, is a general internist and primary care physician, Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He is a Fellow of the American College of Physicians, a Distinguished Fellow of the American Society of Addiction Medicine, and is certified by the American Board of Internal Medicine and the American Board of Addiction Medicine.
Kelly Dunn, Ph.D. is an Associate Professor in the Behavioral Pharmacology Research Unit in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University. Her research interests include mechanisms underlying opioid use disorder and development of effective treatment strategies, comorbid conditions in persons with opioid use disorder, and opioid overdose. Her research also includes randomized controlled evaluations of medications for alcohol use disorder and tobacco use, as well as development of standardized outcome measures.
Ismene L. Petrakis, M.D. is an addiction psychiatrist, a Professor of Psychiatry at the Yale University School of Medicine and the Chief of Psychiatry and Mental Health Services at VA Connecticut Healthcare System. She is also the Director of the Addiction Psychiatry Residency at Yale University School of Medicine and the principal investigator of a National Institute of Drug Abuse (NIDA-T32) training grant. She is certified by the American Board of Psychiatry and Neurology and Addiction Psychiatry.
Frank J. Vocci, PhD, is President and Senior Research Scientist of Friends Research Institute in Baltimore, Maryland. He has previously served as Director of the National Institute on Drug Abuse’s Division of Pharmacotherapies and Medical Consequences of Drug Abuse and is a Fellow and Past-President of The College on Problems of Drug Dependence. His research interests include developing medications for treating nicotine and stimulant use disorder, developing new treamnts for opioid use disorder, and evaluating best practices for treatment of opiate users with criminal justice involvement.
Martha J. Wunsch, MD, FAAP, DFASAM, is a pediatrician and addiction medicine physician with Kaiser Permanente of Northern California. She is program director of the Northern California Kaiser Addiction Medicine Fellowship and Director of the Addiction Medicine Consultation Liaison Service at San Leandro Kaiser Hospital. Dr. Wunsch is the president elect of the American College of Academic Addiction Medicine and a member of the Sub-Board of Addiction for the American Board of Preventive Medicine.